Soft, exophytic anogenital warts caused by low-risk HPV types 6 and 11; high-risk types (16, 18) drive cervical, anal, oropharyngeal cancers — vaccination is highly effective.
Also known as: HPV, human papillomavirus, genital warts, condyloma acuminatum, venereal warts
Overview
Anogenital warts caused predominantly by HPV types 6 and 11 (low-risk for cancer). Distinct from oncogenic HPV types (16, 18 among others) responsible for cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers.
Epidemiology
HPV is the most common STI in the US — most sexually active adults will be infected. Genital warts affect ~1% of sexually active adults at any time. HPV-attributable cancers cause ~36,000 US cases yearly. HPV vaccine (now 9-valent covering types 6/11/16/18/31/33/45/52/58) has dramatically reduced incidence in vaccinated cohorts.
Try two board-style HPV Genital Warts questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1Infectious DiseaseMedium
A 4-year-old girl has a 4-month history of progressive hoarseness and intermittent stridor. She was born vaginally to a mother who had active genital warts at the time of delivery. Direct laryngoscopy reveals multiple friable, cauliflower-like papillomatous lesions involving both true vocal cords. Which of the following is the most appropriate first-line treatment?
AIntralesional cidofovir
BInhaled racemic epinephrine
CSurgical microdebridement
DSystemic acyclovir therapy
ETracheostomy placement
Reveal answer & full explanation
Correct answer: C — Surgical microdebridement
AIntralesional cidofovir
BInhaled racemic epinephrine
CSurgical microdebridement✓
DSystemic acyclovir therapy
ETracheostomy placement
Why Surgical microdebridement is correct
Juvenile-onset recurrent respiratory papillomatosis (JoRRP) is caused by HPV 6 or 11 acquired during vaginal delivery from a mother with genital warts
It is managed primarily with repeated surgical debulking using a CO2 laser or powered microdebrider to maintain a patent airway and preserve voice
There is no curative medical therapy; most children require multiple procedures per year
Adjuvant intralesional cidofovir or systemic bevacizumab is added for aggressive or distally spreading disease
HPV vaccination of the mother before pregnancy and of the child reduces incidence and may slow progression
Why the others are wrong
Systemic acyclovir therapy — treats herpesvirus (HSV/VZV) infections and has no activity against HPV; buzzword-matching a viral airway lesion to an antiviral
Tracheostomy placement — reserved as a last resort for airway obstruction that repeated debulking cannot control; it does not remove the laryngeal papillomas and is avoided when possible because a tracheal stoma is associated with distal tracheal and pulmonary spread of papillomas
Inhaled racemic epinephrine — used for acute croup or transient airway edema; provides only short-lived vasoconstriction and does not address the underlying papillomatous obstruction; premature closure on a stridor-relieving measure
Intralesional cidofovir — unlike acyclovir, this antiviral is actually used in papillomatosis, but only off-label as an adjuvant injected at the time of surgical debulking for aggressive or distally spreading disease; it does not replace debulking, which remains first-line to maintain a patent airway and preserve voice; mistaking an adjuvant for first-line therapy
Question 2Infectious DiseaseEasy
A 3-year-old child is brought to clinic for evaluation of progressive hoarseness and noisy breathing over 6 months. Mother reports the child was born vaginally; she had untreated genital warts during pregnancy. On exam the child has a weak, hoarse cry and biphasic stridor with mild retractions. Direct laryngoscopy shows multiple cauliflower-like exophytic lesions on the true vocal cords. Which of the following is the most likely diagnosis?
ABilateral vocal fold immobility
BRecurrent respiratory papillomatosis
CLaryngeal saccular cyst formation
DPediatric vocal fold nodules
ESubglottic infantile hemangioma
Reveal answer & full explanation
Correct answer: B — Recurrent respiratory papillomatosis
ABilateral vocal fold immobility
BRecurrent respiratory papillomatosis✓
CLaryngeal saccular cyst formation
DPediatric vocal fold nodules
ESubglottic infantile hemangioma
Why Recurrent respiratory papillomatosis is correct
Recurrent respiratory papillomatosis (RRP) is caused by HPV types 6 and 11 transmitted perinatally from a mother with genital HPV infection during vaginal delivery
The juvenile form typically presents between ages 2 and 5 with progressive hoarseness, weak cry, and stridor
Direct laryngoscopy reveals friable cauliflower-like papillomas most commonly on the true vocal cords
Treatment is repeated surgical debulking (CO2 laser or microdebrider), with adjuvant intralesional cidofovir or systemic bevacizumab for aggressive disease
Why the others are wrong
Subglottic infantile hemangioma — presents in the first 6 months with biphasic stridor and may have a cutaneous beard-distribution hemangioma; endoscopy shows a smooth submucosal red mass, not cauliflower lesions (confused-with vascular lesion)
Bilateral vocal fold immobility — causes biphasic stridor and a weak cry but shows immobile cords without exophytic lesions on laryngoscopy, not verrucous papillomas (anchoring on stridor)
Laryngeal saccular cyst formation — presents with a smooth submucosal supraglottic cystic swelling and muffled cry, not cauliflower-like exophytic lesions on the true cords (anchoring on hoarseness)
Pediatric vocal fold nodules — the most common cause of chronic hoarseness in children, from vocal overuse, but nodules are small, smooth, symmetric swellings at the junction of the anterior and middle thirds of the cords that typically cause hoarseness without stridor or retractions, not multiple cauliflower-like exophytic lesions (confused-with the common cause of childhood hoarseness)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full HPV Genital Warts (Condyloma acuminatum) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Early age at first intercourse, multiple lifetime partners
Smoking (impairs clearance and accelerates progression)
Immunocompromise (HIV, transplant) — more extensive disease, higher recurrence
Other STIs
Lack of HPV vaccination
Pathophysiology
HPV is a non-enveloped DNA virus that infects basal keratinocytes through microabrasions. Low-risk types (6, 11) cause epithelial proliferation → warts. High-risk types (16, 18) integrate viral DNA, with E6 and E7 oncoproteins inactivating p53 and Rb → uncontrolled cell cycle progression and malignant transformation over years to decades.
Clinical presentation
Symptoms
Soft, flesh-colored, pink, or gray cauliflower-like (verrucous) papules on genital mucosa, perianal area, or proximal anal canal
Often asymptomatic; may cause pruritus, bleeding with friction, dyspareunia
Warts may coalesce into large plaques (Buschke-Lowenstein giant condyloma, a locally invasive verrucous tumor; more likely with immunosuppression)
Oral/laryngeal lesions possible with oral-genital exposure
High-risk HPV usually asymptomatic until precancer or cancer develops — found on Pap/HPV screening
Soft, fleshy, cauliflower-shaped exophytic anogenital papules in a sexually active adult — condyloma acuminatum. Distinguish from flat moist condyloma lata of secondary syphilis.
Differential diagnosis
Condyloma lata (secondary syphilis) — Moist, flat, gray-white plaques in intertriginous areas; RPR positive
• Ages 30-65: HPV testing alone every 5 years (preferred) OR co-testing (Pap + HPV) every 5 years OR cytology alone every 3 years
• Discontinue at 65 if adequate prior screening and not high-risk
Anal Pap screening: HIV-positive MSM and other high-risk populations; ANCHOR trial supports treatment of HSIL
Test for concurrent STIs
HPV typing not used clinically for wart treatment
Imaging
Anoscopy / high-resolution anoscopy for anal canal lesions
Colposcopy for cervical abnormalities
Diagnostic algorithm
HPV Type Category
Examples
Major Diseases
Vaccine Coverage (Gardasil 9)
Low-risk
6, 11
Genital warts, RRP
Yes (6, 11)
High-risk
16, 18
70% of cervical cancers; anal, oropharyngeal CA
Yes (16, 18)
Other high-risk
31, 33, 45, 52, 58
Additional cervical and anogenital CA
Yes (all 5)
HPV type categories: clinical disease and 9-valent vaccine coverage.
Treatment
First-line
Patient-applied (self-administered):
• Imiquimod 5% cream at bedtime 3 times/week for up to 16 weeks, or 3.75% cream at bedtime every night for up to 8 weeks (wash off after 6-10 h); immune modulator
• Podofilox 0.5% solution/gel — applied BID × 3 days, 4 days off, up to 4 cycles
• Sinecatechins 15% ointment (green tea catechins) — TID up to 16 weeks
Provider-applied:
• Cryotherapy with liquid nitrogen — every 1-2 weeks until clearance
• Surgical removal (excision, electrosurgery, laser ablation) for large or refractory lesions
Cervical and intra-anal lesions require specialty management
No therapy is uniformly effective; recurrence common; choice based on lesion size/location, patient preference, and cost
Second-line / adjunct
Combination or sequential therapy for refractory disease
Intralesional interferon — refractory cases
Cidofovir gel — experimental
HPV vaccine (Gardasil 9) — primary prevention, NOT treatment of existing infection (but recommended through age 26 universally and through age 45 with shared decision-making per ACIP)
Complications
Recurrence (common with all therapies)
Psychosocial distress, sexual dysfunction
Progression of high-risk HPV to cervical, anal, vulvar, vaginal, penile, or oropharyngeal cancer
Recurrent respiratory papillomatosis in infants of mothers with active genital HPV at delivery (rare)
PANCE pearls
HPV vaccine recommended routinely for ages 9-12 (start as early as 9), catch-up to age 26, and shared decision-making 27-45 (ACIP 2019).
Vaccine prevents but does not treat existing infection — vaccinate before sexual debut for maximal benefit.
Cervical screening: primary HPV testing every 5 years at ages 30-65 is now the preferred strategy (ACOG Committee Statement 28, 2026, for clinician-collected samples in average-risk patients; HRSA Women's Preventive Services Guidelines, 2026), while patient-collected samples follow their own interval (ACS repeats a negative self-collected test in 3 years); USPSTF 2018 rates it equal to co-testing every 5 years or cytology every 3 years.
Wart treatments are destructive, not curative — recurrence often reflects residual subclinical infection.
Genital warts caused by low-risk types (6, 11) do not progress to cancer — but high-risk coinfection is common; screen the cervix appropriately.
Juvenile-onset recurrent respiratory papillomatosis (HPV 6/11 acquired perinatally): child typically 2-5 y with progressive hoarseness, weak cry, then stridor; laryngoscopy shows cauliflower-like papillomas on the true vocal cords. Treat with repeated surgical debulking (microdebrider or CO2 laser), adding intralesional cidofovir or systemic bevacizumab for aggressive disease; avoid tracheostomy when possible (associated with distal spread). Cesarean is not indicated solely to prevent HPV transmission (CDC 2021); HPV vaccination is the prevention.
ACIP 2019 — Meites et al., Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (MMWR)
ASCCP 2019 — Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
USPSTF 2018 — US Preventive Services Task Force, Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement (JAMA 2018;320(7):674-686)
HRSA WPSI 2026 — Health Resources and Services Administration, Update to the Women's Preventive Services Guidelines: Screening for Cervical Cancer (Federal Register notice 2025-24235, January 5, 2026)
Practice Infectious Disease questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.